Clasp is pioneering precision in immuno-oncology through next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations common across hard-to-treat cancers. With their unique properties, our TCEs are adaptable for application across a variety of cancers with high unmet need. Focus/Therapeutic Area: Oncology Stage/Status: Series A Website: https://www.clasptx.com/
Clasp Therapeutics Read More »
Advancing off-the-shelf dopamine neuron replacement therapies as a disease-modifying and potentially curative treatment for neurological disorders. Our proprietary platform leverages a novel approach to treating central nervous system disorders, such as Parkinson’s disease, by replacing neurons lost due to neurodegeneration. Focus/Therapeutic Area: Neuro Stage/Status: Series A Website: https://www.kenaitx.com
Kenai Therapeutics Read More »
Tortugas is developing therapeutics for neurological diseases of high unmet need. We focus on translational approaches to allow for rapid identification of efficacy and impact. Focus/Therapeutic Area: Neuro Stage/Status: Series A Website: https://www.tortugasneuro.com/
Tortugas Neuroscience Read More »
